|Ocular drug delivery is very challenging due to the complex and sensitive structure of the eye. Researchers at Purdue University have developed a minimally invasive and effective ocular drug delivery platform. This method enables long term sustained release of therapeutic ocular drugs via a tear-soluble contact lens that leaves behind biodegradable silicon nanoneedles. The tear-soluble contact lens provides an optimal curvature to fit the cornea and it is degraded in less than a minute, enabling initial short-term release of anti-inflammatory drugs and long-term release of therapeutic drugs. This technology directly benefits patients undergoing treatment for chronic diseases or injuries, including glaucoma, cataract, and graft rejection.
- Long term sustained release
- Initial burst release of anti-inflammatory
- Long-term release of therapeutic drugs
- Demonstrated biosafety and efficacy in lab testing
- Ocular drug delivery
- Treatments for glaucoma, cataract, and graft rejection
This technology has been validated for efficacy and safety through successful in vivo testing in a rabbit corneal neovascularization (CNV) model.
Oct 10, 2022
Oct 8, 2021
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906
Phone: (765) 588-3475
Fax: (765) 463-3486